320 related articles for article (PubMed ID: 11050177)
1. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease.
Fontenot AP; Torres M; Marshall WH; Newman LS; Kotzin BL
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12717-22. PubMed ID: 11050177
[TBL] [Abstract][Full Text] [Related]
2. Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP.
Fontenot AP; Newman LS; Kotzin BL
Clin Immunol; 2001 Jul; 100(1):4-14. PubMed ID: 11414740
[No Abstract] [Full Text] [Related]
3. Beryllium presentation to CD4+ T cells is dependent on a single amino acid residue of the MHC class II beta-chain.
Bill JR; Mack DG; Falta MT; Maier LA; Sullivan AK; Joslin FG; Martin AK; Freed BM; Kotzin BL; Fontenot AP
J Immunol; 2005 Nov; 175(10):7029-37. PubMed ID: 16272364
[TBL] [Abstract][Full Text] [Related]
4. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease.
Maier LA; McGrath DS; Sato H; Lympany P; Welsh K; Du Bois R; Silveira L; Fontenot AP; Sawyer RT; Wilcox E; Newman LS
J Immunol; 2003 Dec; 171(12):6910-8. PubMed ID: 14662898
[TBL] [Abstract][Full Text] [Related]
5. HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease.
Lombardi G; Germain C; Uren J; Fiorillo MT; du Bois RM; Jones-Williams W; Saltini C; Sorrentino R; Lechler R
J Immunol; 2001 Mar; 166(5):3549-55. PubMed ID: 11207315
[TBL] [Abstract][Full Text] [Related]
6. Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells.
Fontenot AP; Keizer TS; McCleskey M; Mack DG; Meza-Romero R; Huan J; Edwards DM; Chou YK; Vandenbark AA; Scott B; Burrows GG
J Immunol; 2006 Sep; 177(6):3874-83. PubMed ID: 16951350
[TBL] [Abstract][Full Text] [Related]
7. Linking genetic susceptibility and T cell activation in beryllium-induced disease.
Falta MT; Bowerman NA; Dai S; Kappler JW; Fontenot AP
Proc Am Thorac Soc; 2010 May; 7(2):126-9. PubMed ID: 20427584
[TBL] [Abstract][Full Text] [Related]
8. T cell recognition in chronic beryllium disease.
Amicosante M; Fontenot AP
Clin Immunol; 2006 Nov; 121(2):134-43. PubMed ID: 16697706
[TBL] [Abstract][Full Text] [Related]
9. Major histocompatibility locus genetic markers of beryllium sensitization and disease.
Saltini C; Richeldi L; Losi M; Amicosante M; Voorter C; van den Berg-Loonen E; Dweik RA; Wiedemann HP; Deubner DC; Tinelli C
Eur Respir J; 2001 Oct; 18(4):677-84. PubMed ID: 11716174
[TBL] [Abstract][Full Text] [Related]
10. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease.
Richeldi L; Sorrentino R; Saltini C
Science; 1993 Oct; 262(5131):242-4. PubMed ID: 8105536
[TBL] [Abstract][Full Text] [Related]
11. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease.
Fontenot AP; Maier LA
Trends Immunol; 2005 Oct; 26(10):543-9. PubMed ID: 16099719
[TBL] [Abstract][Full Text] [Related]
12. Role of the HLA-DP Glu 69 and the TNF-alpha TNF-alpha 2 gene markers in susceptibility to beryllium hypersensitivity.
Rogliani P; Amicosante M; Berretta F; Dotti C; Bocchino M; O'Donnell KM; Saltini C
Int J Immunopathol Pharmacol; 2004; 17(2 Suppl):3-10. PubMed ID: 15345185
[TBL] [Abstract][Full Text] [Related]
13. HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells.
Amicosante M; Berretta F; Franchi A; Rogliani P; Dotti C; Losi M; Dweik R; Saltini C
Eur Respir J; 2002 Nov; 20(5):1174-8. PubMed ID: 12449171
[TBL] [Abstract][Full Text] [Related]
14. Beryllium-induced tumor necrosis factor-alpha production by CD4+ T cells is mediated by HLA-DP.
Sawyer RT; Parsons CE; Fontenot AP; Maier LA; Gillespie MM; Gottschall EB; Silveira L; Newman LS
Am J Respir Cell Mol Biol; 2004 Jul; 31(1):122-30. PubMed ID: 14975942
[TBL] [Abstract][Full Text] [Related]
15. Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69.
Amicosante M; Berretta F; Rossman M; Butler RH; Rogliani P; van den Berg-Loonen E; Saltini C
Respir Res; 2005 Aug; 6(1):94. PubMed ID: 16098233
[TBL] [Abstract][Full Text] [Related]
16. Activation pathways implicate anti-HLA-DP and anti-LFA-1 antibodies as lead candidates for intervention in chronic berylliosis.
Chou YK; Edwards DM; Weinberg AD; Vandenbark AA; Kotzin BL; Fontenot AP; Burrows GG
J Immunol; 2005 Apr; 174(7):4316-24. PubMed ID: 15778396
[TBL] [Abstract][Full Text] [Related]
17. Beryllium-Induced Hypersensitivity: Genetic Susceptibility and Neoantigen Generation.
Fontenot AP; Falta MT; Kappler JW; Dai S; McKee AS
J Immunol; 2016 Jan; 196(1):22-7. PubMed ID: 26685315
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Analysis of CD4
Hyun YS; Jo HA; Lee YH; Kim SM; Baek IC; Sohn HJ; Cho HI; Kim TG
Front Immunol; 2020; 11():602014. PubMed ID: 33658991
[TBL] [Abstract][Full Text] [Related]
19. HLA class II DPB1 and DRB1 polymorphisms associated with genetic susceptibility to beryllium toxicity.
Rosenman KD; Rossman M; Hertzberg V; Reilly MJ; Rice C; Kanterakis E; Monos D
Occup Environ Med; 2011 Jul; 68(7):487-93. PubMed ID: 21186201
[TBL] [Abstract][Full Text] [Related]
20. Self-presentation of beryllium by BAL CD4+ T cells: T cell-T cell interactions and their potential role in chronic beryllium disease.
Fontenot AP; Edwards DM; Chou YK; Mack DG; LaTocha D; Vandenbark AA; Burrows GG
Eur J Immunol; 2006 Apr; 36(4):930-9. PubMed ID: 16552706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
